However, with a pair of BsAbs designed to c-arget lonin via CD22 and CD38, the cytotoxicity achived equalEd that obtained with a pair of anti-CD22 BsAbs (IC"= 1 x 10-" M). This important result suggests that the anti-CD38 helps bind the Fonin to the cell and is then 'dragged' or 'piggy-bcked' into the cel by the anti-CD22 BsAb. The implication of these findings for cancer therapy is discussed.
Using pairs of anti-CD22 BsAbs we were able to genrate bivalent BsAb-genmm complxs whch achived IC valies of 2 x 10-" M geomn, a potency which is equivalent to that reache by saporin in this tag system. However, beus geoin is 5-10tImes less toxic than saporin, the thrapeutic ratio for geloin is superior, making it potentially a more useful agnt for human treatment Cytotoxicity assays and kinetic anablsis showed that targeting geonin via CD38 was 2-5 tmes k effective than dlivy though CD22.
However, with a pair of BsAbs designed to c-arget lonin via CD22 and CD38, the cytotoxicity achived equalEd that obtained with a pair of anti-CD22 BsAbs (IC"= 1 x 10-" M). This important result suggests that the anti-CD38 helps bind the Fonin to the cell and is then 'dragged' or 'piggy-bcked' into the cel by the anti-CD22 BsAb. The implication of these findings for cancer therapy is discussed. (Raso and Griffin, 1981; Glenie 1988) . Unlike ITs in which the toxin is chemically conjugated directy to an antibody molcule (Vitetta et al., 1987; Blakey and Thorpe, 1988) , with BsAbs the RIP is held in one of the antigen binding sites, while the second antigen-binding arm is used to deliver the RIP to an appropriate target molecule on the unwanted cell. The potential advantages of this targeting systm include the avoiance of chemical modification of the toxin or antibody and the ability to release the toxic moiety from the antibody once inside the cell without the need to reduce a disuphide bond. In addition, in certain situations it may be possible to use BsAbs in a two-step delvery system in which the BsAb is first and allowed to reach maximum localisation ratio (tumour-normal tissue), before giving the short-lived toxic moiety for capture by the prelocalised antibody. This type of two-stage ddivery system is being apphed very successfully to the radiom g of tumours with BsAbs and radionulide (Peltier et al., 1993) . Clearly, the major disadvantage with the BsAb targeting strategy is its relance on the comparatively weak noncovalent interactions between the BsAbs and the toxin to hold the complex together while it is delivered to the appropriate target.
We have shown previously that, in both leukaemic animals (Glennie et al., 1988; French et al., 1991) and lymphoma paients (Bonardi et al., 1992) , bispecific F(ab% antibody with dual specfiity for the RIP saporin and a tumour marker can be highly efficient at delivering saporin and eradicating tumour cells. However, optimal results are achieved only if certain rules are followed: first, the BsAbs must be used as complementary pairs of reagents which recognise different, non-blocking, epitopes on the saporin molecule and so provide bivalent attachment of the toxin to the target cell (French et al., 1991) ; and, second, a tumour marker must be slcted which is capable of transporting the RIP inside the cell (Bonardi et al., 1993) . To date we have asessed the performance of BsAbs designed to deliver saporin via a range of surface antigens on neoplastic B cells, such as Ig, CD19, CD22 and CD37, and found that CD22 is by far the most effcient in this respect (Bonardi et al., 1993) .
In by water extraction as described previously (Stirpe et al., 1980 (Stirpe et al., , 1983 to 5 x 106 ml') was then added and the incubation continued for a further 1 h at 37C. Endocytosis of saponn-BsAb complexes was prevented by inclusion of sodium azide (15 mM) and 2-deoxyglucose (50 mM). The cells were then separated from the aqueous phase by centrifugation through phthalate oils as described previously (French et al., 1991) .
Results

Generation of anti-gelonin antibodies
In the current work six monoclonal anti-gelonin MAbs were raised, anti-gel-l to anti-gel-6. Our previous investigations using BsAbs to deliver saporin to lymphoma cells has shown that selected pairs of BsAbs that recognise different epitopes on saporin outperform single derivatives (French et al., 1991; Bonardi et al., 1993) . In order to identify pairs of MAbs recognising different epitopes on the gelonin molecule, the panel of anti-gelonin MAbs was epitope mapped using the LAsys. This allows the interaction of molecules to be studied in real time, thereby allowing rapid analysis of macromolecular interactions.
Epitope mapping was accomplished by immobilising the antigen, gelonin, onto the dextran hydrogel that lies on top of the sensing surface. A sample of one of the MAbs was added to the cuvette and its binding followed until it was close to equilibrium. A second MAb was then added to determine whether it would bind to the gelonin in the presence of the first MAb. A typical trace is shown in Figure  1 , which demonstrates that the anti-gel-3 blocks the binding of anti-gel-6 to gelonin, but not the binding of anti-gel-2 or anti-gel-5. Three MAbs, anti-gel-2, anti-gel-3 and anti-gel-5, one Ab from each group, were selected for further analysis. The kinetics of the interaction of their Fab' fragments with gelonin were determined using the lAsys with the gelonin immobilised to the sensing surface and the Fab' added to the cuvette. The inset to Figure 2 shows a typical trace for Fab' fragments from an anti-gelonin MAb, demonstrating the association and dissociation phases of the reaction at three different concentrations of MAb. When kj. is plotted against antibody Fab' concentration (Figure 2) , the slope of the resulting straight line gives the k.. The kd. (also known as the kff, kd or k-1) was determined directly from the dissociation phase of the data. Table II shows the km, kd, and K& values obtained with Fab' fragments of the three anti-gelonin MAbs used throughout the remainder of this paper. All three MAbs had similar association rate constants, but there is a 10-fold difference in their dissociation rate constants, being in the order anti-gel-5 < anti-gel-3 < anti-gel-2. Thus, the derived Fab' dissociation equilibrium constants (Kd) were in Using the lAsys resonant mirror biosensor the first MAb was allowed to bind for 25-30 min in the gelonin-coated cuvette. After three washes in PBS-Tween, the second MAb was added to assess whether it was able to bind (+) or was blocked (-), as described in Figure 1 . Three distinct, non-blocking, epitopes were identified shown by anti-gel-2, anti-gel-3 and anti-gel-5. Time (s)
Fugwe 1 Epitope mapping of anti-gelonin MAbs using the lAsys system. Each of the four MAb Fab' fragments, anti-gel-3, -6, -2 and -5, was added sequentially to the gelonin-coupled sensing surface as indicated (arrows) at a final concentration of 20 pg ml-' and their association followed. The result indicates that the epitopes recognised by anti-gel-3, anti-gel-2 and anti-gel-5 are independent and non-blocking, while the epitope recognised by anti-gel-6 is almost completely blocked by anti-gel-3. A complete breakdown of the epitope mapping for all the anti-gelonin MAbs is given in Table I .
Antibody concentration (107 x M)
FIgwe 2 Determination of km and k&., for the anti-gel-2 MAb using the resonant mirror biosensor. The association and dissociation phases of Fab' anti-gel-2 binding to gelonin were monitored at five concentrations over the range 0.25 x 10-7 M to 4 x 10-7 M. For each MAb concentration investigated, the association and dissociation phases were followed for 5 min followed by a 2 min wash with 50 mm hydrochloric acid to remove bound antibody. The inset shows the traces obtained at the three highest concentrations: I, 4 x 10-7 M; II, 2 x 10-7 M; HI, I X 10-7 M. The observed rate constant (ko) at each MAb concentration was determined using the FASTfit program. Main figure: The plot of kl. against the MAb concentration gives a straight line with a slope of km and an intercept with the y-axis of kd, the order anti-gel-5<anti-gel-3 <anti-gel-2, with anti-gel-5 having a 10-fold higher affinity than anti-gel-2. For com-
parison, of I x 10-10 M. However, by far the most efficient delivery system, as in previous work (French et al., 1991) , was obtained using pairs of BsAbs which had been selected to recognise non-blocking epitopes on the gelonin molecule in the epitope mapping studies described above. With the three complementary combinations of BsAbs, anti-gel-2 + anti-gel-3, anti-gel-3 + anti-gel-5 and anti-gel-2 + anti-gel-5, the IC50 is approximately 2 x 101I1 M, giving an approximately 50 000-fold increase in toxicity over gelonin alone. Figure 3 shows the result for [anti-gel-3 x anti-CD22] + [anti-gel-5 x anti-CD22], which was typical of these pairs of derivatives. This level of toxicity is very similar to that achieved using a complementary pair of anti-saporin BsAbs (Figure 3) (Figures 3 and 4) . Figure 5a shows The results in Figure Sb show similar data for radiolabelled gelonin binding to Daudi cells via anti-CD38 BsAb. In general, CD38-specific BsAbs capture between two and three times more RIP than CD22 BsAb. This difference reflects the increased level of CD38 expression on Daudi cells (unpublished observations). As with the CD22-specific reagents, we obtained a sizeable increase in avidity using a pair of anti-CD38 BsAbs, allowing approxiimately 250 000 molecules of gelomnn to bind to each cell at 3 x 10-9 M toxin.
Figure Sb also shows that very similar levels of binding were achieved when gelonin was tethered via CD38 alone using a pair of CD38-specific BsAbs, or via CD38 and CD22 using a combination of CD38-and CD22-specific BsAbs.
Using these binding data we were able to estimate, for each BsAb and each combination of BsAbs, the number of gelonin or saporin molecules bound to the target cells at their respective IC50 values obtained in toxicity studies (Figures 3   and 4) . The results are summarised in Table III (0.02-20 iLg ml-) were investigated for each single or pair of anti-CD22 BsAbs. The maximum rate of inhibition was achieved when saporin or gelonin was included at a concentration of 2 gig ml' or above (Figure 6a, inset) . In all subsequent experiments RIPs were used at 2 gmg11. Figure 6a (main figure) shows the rate of inhibition of [3Hpeucine incorporation with CD22-specific BsAbs. In all cases there was a lag period of at least 6 h before any inhibition was recorded. When the inhibition of [3Hjeucine uptake did com- Gdouin deby Ifmnphoo.n cek RR French et al 991 mence, saporin was significantly more active than gelonin, achieving 90% inhibition by 24 h. By extrapolation, gelonin would have taken around 40 h to achieve this level of inhibition. Interestingly, the rate of inhibition was the same whether the toxin was delivered by a single BsAb or by a combination of BsAbs.
When gelonin is delivered via CD38 (Figure 6b ), again we see a long lag period before any inhibition of protein synthesis can be measured. This is followed by even slower kinetics for the inhibition of protein synthesis than when gelonin was targeted via CD22, and by extrapolation [3Hlleucine uptake would have taken around 60 h to be reduced to 10% of the control level. However, one of the most important findings from this work is that, when gelonin is delivering via CD22 and CD38, using a mixed cocktail of BsAbs, the rate of inhibition increases to that achieved with anti-CD22 BsAbs. Thus, by delivering through two surface antigens, we have increased the activity of the CD38 denrvative to that of the anti-CD22 BsAb.
Disussio
In the current work we have investigated anti-CD22-and anti-CD38-specific BsAbs for the delivery of gelonin against neoplastic B cells. Six new anti-gelonin MAbs were raised by conventional MAb technology and then epitope mapped on gelonin using the IAsys. The LAsys allowed rapid analysis of the binding characteristics of the new MAbs and proved extremely efficient at identifying MAbs which recognised different, non-overlapping epitopes on gelonin. From the panel of MAbs, three (anti-gel-2, -3 and-5) were selected as recognising non-blocking epitopes on gelonin. The Kd of these MAbs ranged from approximately 1 x 10' to 6 x 19-9 M, with two MAbs, anti-gel-3 anti-gel-5, having respectively three and ten times higher affinity than the best of our anti-saporin MAbs, anti-sap-l (Table II) . Interestingly, one of us (AJTG) has shown that a major difference between these anti-gelonin MAbs and a panel of our antisaporin MAbs is that in general the latter have strik-ingly faster off-rates. The results in Table H show that the three anti-gelonin MAbs have kdi values which are between 6 and 50 times slower than anti-sap-l. One possible explanation for this disparity is that during an immune response, because saporin is more toxic than gelonin, most responding B cells may be kiled as a result of internalising even a small amount of saporin via their surface Ig. However, those B cells which express surface antibody with a very fast off-rate may engage saporin briefly and achieve activation before the toxin has been camed inside the cell (George et al., 1994 (2 x 10-" M) which was effectively equivalent to that given by saporin (1.5 x 10-" M) ( Figure 3 and Table III Previous work has shown that CD22 (Bonardi et al., 1993) , CD25 (Tazzari et al., 1993) (Bonardi et al., 1993) . It is now evident that CD38 can also be used to target RIP in this delivery system. However, its performance, while much better than that of CDl9 and CD37, is not as good as that of CD22. The IC_o values achieved with anti-CD38 BsAbs were 2-10 times higher than with equivalent anti-CD22 reagents, and most importantly the toxicity curves often failed to reach the baseline, showing that the inhibition of protein synthesis was not complete. Binding data strongly suggest that, despite high levels of expression, Daudi cells either internalise CD38 poorly or deliver CD38-bound BsAb-RIP complexes to an inappropriate compartment inside the cell which prevents efficient translocation of RIPs into the cytosol. For example, between 35000 and 60 000 molecules of gelonin are needed on the surface of each cell to achieve half-maximum inhibition of protein synthesis. These values compare with 6000-10000 molecules per cell when gelonin is targeted via CD22 (Table  III) . Similarly, the failure of anti-CD38 derivatives to block protein synthesis completely and the relatively slow kinetics of the inhibition probably reflect poor internalisation relative to CD22.
Perhaps the most interesting finding to emerge from the current work comes from using combinations of BsAbs which engage two distinct cellular targets simultaneously. Using a compklmentary pair of anti-gelonin BsAbs, one targeting CD22 and the other CD38, we have produced a complex which delivers gelonin to Daudi cells with an efficiency which is close to that achieved by our best CD22 derivatives. Using the most effective pair of anti-CD38 BsAbs, gelonin toxicity could be increased about 11 000 times over that of the free RIP. However, with a mixed pair of BsAbs which target CD22 and CD38 simultaneously, we have increased gelonin toxicity approximately 130000 times. Thus, this cocktail is delivering gelonin with an efficiency which is equal to that of the pair of anti-CD22 BsAbs. The binding data confirm this intepretation, showing that, while a pair of anti-CD38 BsAbs needs to capture 60 000 gelonin molecules per cell to achieve half-maximum inhibition, the anti-CD22/anti-CD38 BsAbs accomplished this with only 12 000 gelonin molecules per cell, a value which is very similar to that given by the pair of CD22 BsAbs. Thus, by binding CD22 and CD38 simultaneously we appear to gain the advantages of capturing the RIP molecules bivalently and internalising them with the efficiency of CD22. The most likely explanation for this finding is that the anti-CD22 arm of the anti-CD22/anti-CD38/gelonin complex is 'dragging' or 'piggy-backing' the CD38 molecules inside the cells. It may be that the high density of CD38 on the target cells facilitates the initial capture of the complex via its anti-CD38 arm with subsequent binding of the anti-CD22 arm. For future patient therapy, targeting dual antigens in the way described looks very attractive. Antigen density on tumour cells will effectively be increased, and variant cells which fail to express one or other of the target antigens may be susceptible to killing via the second.
We conclude that the targeting system which has been developed for gelonin will complement the saporin system which is currently being evaluated in clinical trials (Bonardi et al., 1992) . Because of its relative lack of toxicity, gelonin is clearly an attractive RIP for human treatment and gives a large therapeutic 'window' when targeted with BsAbs. In addition, we anticipate being able to use BsAb-saporin and BsAb-gelonin complexes in combination in individual patients. Thus, when treatment with one RIP results in an anti-RIP response, the RIP will be changed and the period of treatment thereby extended.
